Cellestis firms up Japanese deal

By Melissa Trudinger
Monday, 20 October, 2003

Diagnostic company Cellestis has completed an amendment to its distribution agreement with Japanese company Nichirei, covering price and minimum volumes for its second generation TB test QuantiFERON-TB GOLD.

Cellestis managing director Dr Tony Radford said in a statement that subject to approval of the test for sale in Japan, the amended agreement has a minimum product purchase requirement in excess of AUD$2 million during the first 2 years post-approval. The company hoped its agreement with Nichirei would help it exceed its minimum volume targets, he said.

Nichirei and Cellestis submitted an application for approval to the Japanese regulatory authorities in May this year, but approval is not expected before May 2004 at the earliest.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd